Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...
As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...
J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense ...
Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...
Yonhap News English on MSN16h
Samsung Bioepis launches autoimmune disease treatment in U.S.Pyzchiva, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is Samsung ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...
Australia's corporate regulator said on Tuesday the country's stock market operator would be required to publish a comparison ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback